HHRI News & Press Releases
September 22, 2026 -- A transition is underway in the management of the nation's transplant data infrastructure. Publicis Sapient, a global digital business transformation company, is in the process of taking over fundamental elements of the Scientific Registry of Transplant Recipients (SRTR) contract, from the Hennepin Healthcare Research Institute (HHRI). The transition is currently in progress. The IT infrastructure transition is expected to be fully completed by December 1, 2026, with other contract element timelines yet to be determined.
SRTR is a vital national resource that supports the transplant community through comprehensive data analysis, with a core mission of improving patient outcomes and experience. It operates under a contract from the Division of Transplantation (DoT), Health Systems Bureau (HSB), Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services (HHS). The registry provides program-specific reports on transplant programs and organ procurement organizations, offering wide-ranging information to clinicians, researchers, and patients.
HHRI has been a cornerstone of medical research since 1952, supporting and overseeing research conducted at HCMC, the flagship acute care and teaching hospital of the Hennepin Healthcare System in downtown Minneapolis. As one of the largest medical research nonprofits in Minnesota, HHRI often ranks in the top ten percent nationally of institutions receiving research grants from the National Institutes of Health (NIH). The organization, through its Chronic Disease Research Group (CDRG), has operated SRTR for over 15 years with a steadfast commitment to its mission of transforming health and health care for all through ethical research and meaningful community partnerships.
The transition from HHRI to Publicis Sapient is being conducted collaboratively to ensure a seamless transfer of responsibilities and the continued integrity of SRTR's operations. Both organizations are dedicated to ensuring that the registry continues to provide reliable, data-driven insights that are essential for the transplant community and the patients they serve.
Further updates will be provided as the transition progresses.
More HHRI Research Highlights
Halfway Through 2026: A Look Back at HHRI’s Year So Far
If you can believe it, we’re already more than halfway through 2026! In case you missed it (ICYMI), here’s a curated round-up of some of HHRI’s biggest stories from the first half of the year. Cold Realities: How Science and Speed Save Lives in Frostbite Emergencies Living in Minnesota is…
Read MoreWhen Evidence Changes Practice: Rethinking Aspirin in Older Adults
Most people want to live long, healthy lives and age well. As a geriatrician, a doctor specializing in the care of older persons, Anne Murray, MD, MSc, has pursued research to help patients achieve a healthy lifespan, or an independent life without dementia or disability. Dr. Murray is an internal…
Read MoreASPREE-XT (eXTension) study receives $42.3 million to determine longer-term effects of aspirin on health
The ASPREE-XT (eXTension)* study was recently awarded $42.3 million in funding from the National Institute On Aging of the National Institutes of Health (NIH). The five-year grant enables researchers to study if there are possible long-term health benefits of being on low-dose aspirin. ASPREE-XT is led by the Berman Center…
Read MoreASPREE study – A Game Changer in Healthcare
The New England Journal of Medicine named the ASPirin in Reducing Events in the Elderly (ASPREE) study one of the 12 most notable articles in 2018 that had an impact on medicine. Led by Hennepin Healthcare Research Institute investigator Anne M. Murray, MD, MSc, in Minneapolis and John J. McNeil,…
Read MoreDaily low-dose aspirin found to have no effect on healthy life span in older people
Large NIH-funded study examined outcomes in United States and Australia. In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living (life free of dementia or persistent physical disability). Risk of…
Read More